Revenue
2015
2016
Eledon Pharmaceuticals, Inc. (ELDN)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | $0 | $0 | — | — | — |
| Research & development | $66.3M | $52.0M | $30.3M | $27.1M | $23.7M | $6.1M | $8.1M | $6.8M | $2.0M | $3.2M | $32.6M | $14.6M | $12.2M | $7.4M |
| Operating expenses | $83.3M | $70.6M | $43.0M | $88.4M | $36.9M | $18.5M | $16.1M | $14.1M | $13.1M | $5.1M | $45.3M | $23.5M | $15.7M | $9.6M |
| Operating income | — | — | −$43.0M | −$88.4M | −$36.9M | −$18.5M | −$16.1M | −$14.1M | −$13.1M | −$5.1M | −$45.3M | −$23.5M | −$15.7M | −$9.6M |
| EBITDAderived | — | — | — | — | — | −$18.5M | −$16.0M | −$14.0M | −$13.1M | −$5.1M | — | — | — | — |
| Net income | −$45.6M | −$36.2M | −$116.5M | −$88.0M | −$34.5M | −$22.8M | −$16.0M | −$14.1M | −$13.1M | −$5.7M | −$45.1M | −$23.3M | −$15.7M | −$9.6M |
| Basic EPSper diluted share | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | -$15.72 | -$24.42 | -$1.56 | -$2.30 | -$2.46 | -$2.01 | -$3.60 | -$38.02 | -$31.09 |
| Diluted EPSper diluted share | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | -$15.72 | -$24.42 | -$1.56 | -$2.30 | -$2.46 | -$2.01 | -$3.60 | -$38.02 | -$31.09 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 29, 2024Form 4 | BIOTECHNOLOGY VALUE FUND II LP +9Other | BuyPre-funded Warrants to Purchase Common Stock · derivative | 440.5K | $3.65 | $1.61M | 838.5K |
| Oct 29, 2024Form 4 | BIOTECHNOLOGY VALUE FUND II LP +9Other | BuyPre-funded Warrants to Purchase Common Stock · derivative | 2.10M | $3.65 | $7.67M | 6.24M |
| Oct 29, 2024Form 4 | BIOTECHNOLOGY VALUE FUND II LP +9Other | BuyPre-funded Warrants to Purchase Common Stock · derivative | 2.21M | $3.65 | $8.08M | 7.42M |